A c c e p t e d M a n u s c r i p t Respiratory syncytial virus (RSV) is an important respiratory pathogen which is estimated, globally, to cause at least 33 million episodes of lower respiratory tract infection (LRTI) in children younger than five each year. 1 These LRTIs result in at least 3 million hospitalizations and approximately 120,000 deaths. 1 Because of the morbidity and mortality associated with RSV, especially in low to middle income countries, preventative methods such as vaccines and monoclonal antibodies are currently a topic of intense research. 2 There are currently three strategies aimed at RSV prevention in children under two years of age. 3 These include maternal vaccination, passive antibody administration, and pediatric immunization. 3 The advantages and disadvantages of each strategy are affected by the peak incidence of severe disease and overall disease burden estimates. These estimates not only inform cost-benefit projections, but also demonstrate specific populations that will have increased or decreased benefits to a particular prevention strategy. 4 One such population are infants born premature.
It is known that the risk of LRTI and subsequent hospitalization from RSV has an inverse relationship with both gestational age at the time of delivery and chronological age at the time of infection. 5, 6 However, the clinical impact of RSV on premature infants is an area where additional data will better inform prevention strategies. The article entitled The authors found that in their cohort of premature infants 0-12 months of age 3.83/1,000 infants suffered respiratory failure due to RSV and 0.8/1,000 infants died. This A c c e p t e d M a n u s c r i p t mortality rate was three times that of term infants in the same population. 7 This direct comparison of mortality statistics between term and preterm infants in the same population providesmuch needed data. This was demonstrated in a recent meta-analysis that was unable to draw conclusions about RSV mortality in preterm infants because of lack of data. 8 And while premature infants only account for ~10.6% of infants born worldwide, they represent a disproportionate quantity and risk for hospitalizations, intensive care unit admissions and respiratory failure due to RSV. 9, 10 These clinical data illustrate why preventative strategies must account for premature infants as well as term infants.
Because of the recent RSV vaccine clinical trials, maternal vaccination and passive monoclonal antibody administration have probably generated the most excitement for RSV prevention. Based on the successes of maternal vaccination in preventing infantile tetanus, pertussis and influenza, RSV maternal vaccination offers many potential advantages.
Maternal RSV vaccination, typically administered in the second and third trimesters (28-34 weeks), has shown good immunogenicity in the mothers as well as efficient transplacental antibody transfer. 11 , 12 These antibodies, if effective, would then protect the infant during the first 3 to 6 months of life, which is the period of highest severity and mortality due to RSV. 1,5,11 , 12 The issue with maternal RSV vaccines, specifically for preterm infants, is that many infants may not receive sufficient antibody concentrations for protection, as transplacental transfer of antibody does not begin until approximately 32 weeks gestation. 13 Additionally, because vaccination may occur in the third trimester, some women will either not receive the vaccine prior to delivery or have insufficient time to generate and transmit a peak antibody response post-vaccination.
The second preventative method for which there is already an approved product is passive immunization through RSV specific antibody administration. Palivizumab has been shown to be safe and effective in specific populations; however, it has the drawback of has surrounded recent monoclonal antibodies that are longer lasting and require fewer administrations. However, as shown by REGN2222, a monoclonal antibody that was unsuccessful, mutations in the virus may hinder the effectiveness of such a specific antibody. 13 This strategy, however, remains the most promising for young premature infants as transplacental antibody transfer is not required for protection.
The third preventative method is active vaccination of infants. An effective vaccine could be administered at some point during the first year of life to provide immunity at minimum for the RSV season. A potential issue with early administration of infant vaccines is maternal antibody interference. A substantial number of mothers will transfer high levels of RSV specific antibody to their infants due to a previous infection with RSV prior to or during pregnancy. 11, 12, 15 There are concerns that high levels of maternally derived RSV-specific antibodies will interfere with vaccine effectiveness in young children. 16 For this reason, many pediatric RSV vaccine studies are targeting infants 4 to 6 months and older. 2 Consideration could be given to a two-dose administration series at 4 and 6 months, concurrently with the other infant vaccines, and then annually with influenza vaccines. This strategy leaves infants less than six months of life, especially those that are premature, still at risk for substantial morbidity and mortality from RSV. Infant vaccination, however, can complement maternal vaccination or passive monoclonal antibody administration by initiating the vaccination series at a time when both antibody protection and antibody interference are waning.
Together, the above vaccination strategies offer substantial promise for the future of RSV prevention. It is likely that in time an RSV vaccine and/or long acting monoclonal antibody will be approved for commercial use.However, we would suggest that overlapping strategies will be needed to protect all infants and young children. We agree with others that various vaccine formulations with overlapping vaccination strategies will be needed to for such strategies, as substantial mortality will continue in low resource settings without an effective RSV prevention method for term and pre-mature infants. We think that the future is bright for RSV prevention, but continued data collection on the morbidity and mortality of RSV in high risk populations, including term-infants, is necessary to guide that future.
